Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. More Details
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Protara Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TARA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TARA's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how TARA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TARA performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Protara Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StCould The Protara Therapeutics, Inc. (NASDAQ:TARA) Ownership Structure Tell Us Something Useful?
3 months ago | Simply Wall StHave Protara Therapeutics, Inc. (NASDAQ:TARA) Insiders Been Selling Their Stock?
4 months ago | Simply Wall StHave Insiders Sold Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Recently?
Is Protara Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TARA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TARA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TARA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: TARA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TARA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TARA is overvalued based on its PB Ratio (1098x) compared to the US Biotechs industry average (3.5x).
How is Protara Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TARA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TARA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TARA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if TARA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if TARA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TARA's Return on Equity is forecast to be high in 3 years time
How has Protara Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TARA is currently unprofitable.
Growing Profit Margin: TARA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TARA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TARA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TARA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.2%).
Return on Equity
High ROE: TARA has a negative Return on Equity (-2357.86%), as it is currently unprofitable.
How is Protara Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: TARA's short term assets ($1.8M) do not cover its short term liabilities ($1.9M).
Long Term Liabilities: TARA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TARA is debt free.
Reducing Debt: TARA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if TARA has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TARA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Protara Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TARA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TARA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TARA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TARA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TARA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jesse Shefferman (48 yo)
Mr. Jesse Shefferman is the Co-Founder of Proteon Therapeutics Inc. (Formerly known as Protara Therapeutics, Inc. (formerly known as ArTara Therapeutics, Inc.).) and also serves as its President & CEO sinc...
CEO Compensation Analysis
Compensation vs Market: Jesse's total compensation ($USD379.08K) is below average for companies of similar size in the US market ($USD1.12M).
Compensation vs Earnings: Jesse's compensation has increased whilst the company is unprofitable.
|Independent Chairman of the Board||no data||US$111.63k||0.50% |
|Independent Director||0.92yr||US$3.75k||no data|
|Independent Director||1yr||US$6.38k||no data|
|Independent Director||no data||US$82.88k||0.079% |
|Independent Director||1.83yrs||US$84.38k||0.098% |
|Director||0.33yr||no data||no data|
Experienced Board: TARA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TARA insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: TARA only recently listed within the past 12 months.
Protara Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Protara Therapeutics, Inc.
- Ticker: TARA
- Exchange: NasdaqGM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$255.069m
- Shares outstanding: 11.21m
- Website: https://www.protaratx.com
Number of Employees
- Protara Therapeutics, Inc.
- 1 Little West 12th Street
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TARA||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 2020|
|1KPA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2020|
Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/23 23:46|
|End of Day Share Price||2020/11/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.